Chemomab Therapeutics

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class monoclonal antibody designed to neutralize C... CL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported encouraging results from a Phase 2 liver fibrosis biomarker study in NASH patients and an investigator study in patients with severe lung injury. A global Phase 2 trial in primary sclerosing cholangitis patients (PSC) is ongoing. Patient enrollment in the trial is complete with a top-line data readout targeted for midyear 2024. CM-101 has Orphan Drug designation in the U.S. and European Union and received Fast Track designation for the treatment of PSC in adults from the U.S. Food and Drug Administration (FDA).Read More